Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Netupitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.75 |
| ▸ | TACR3 | P29371 | 5/20 | 0.66 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Netupitant SCHEMBL29809811 | 1.00 | TACR1 (1.00) | TACR1CYP3A4TACR3GPBAR1 | |
| Netupitant SCHEMBL30800106 | 0.99 | TACR1 (0.98) | TACR1CYP3A4TACR3GPBAR1 | |
| Netupitant SCHEMBL17222804 | 0.99 | TACR1 (0.98) | TACR1CYP3A4TACR3GPBAR1 | |
| Netupitant SCHEMBL6637560 | 0.99 | TACR1 (0.98) | TACR1CYP3A4TACR3GPBAR1 | |
| SCHEMBL23895400 | 0.97 | TACR1 (0.95) | TACR1CYP3A4TACR3GPBAR1 | |
| SCHEMBL13921492 | 0.97 | TACR1 (0.95) | TACR1CYP3A4TACR3GPBAR1 | |
| SCHEMBL15678883 | 0.94 | TACR1 (0.89) | TACR1CYP3A4TACR3GPBAR1 | |
| SCHEMBL1399445 | 0.91 | TACR1 (1.00) | TACR1CYP3A4TACR3GPBAR1 | |
| SCHEMBL4128039 | 0.91 | TACR1 (0.84) | TACR1CYP3A4TACR3GPBAR1 | |
| SCHEMBL1399446 | 0.91 | TACR1 (0.84) | TACR1CYP3A4TACR3GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2463 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260102417-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER | KEYZELL HOLDING S L (ES) | 2026-04-16 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-20260027138-A1 | PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT | HELSINN HEALTHCARE SA (CH) | 2026-01-29 | — | — | US | claimed |
| US-20260027088-A1 | Inhibitors of Glutathione S-Transferases (GSTS) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1), Pharmaceutical Compositions, and Uses in Managing Cancer | UNIV EMORY (US) | 2026-01-29 | — | — | US | claimed |
| EP-4683713-A1 | DEUTERATED P2X3 MODULATORS | GlaxoSmithKline Intellectual Property (No.3) Limited (GB) | 2026-01-28 | — | — | EP | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| EP-1349541-A1 | SELF EMULSIFYING LIPID MATRIX (SELM) | F. Hoffman-la Roche AG (CH) | 2003-10-08 | — | — | EP | claimed |
| US-20030083345-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-01 | — | — | US | claimed |
| WO-2003006016-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS WITH PYRIDINIC STRUCTURE, FOR THE TREATMENT OF BRAIN, SPINAL OR NERVE INJURY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-23 | — | — | WO | claimed |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | claimed |
| WO-2002085458-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | F. HOFFMAN-LA ROCHE AG (CH) | 2002-10-31 | — | — | WO | claimed |
| US-20020114837-A1 | Galenic composition for low bioavailability medicaments | F.HOFFMANN-LA ROCHE AG (CH) | 2002-08-22 | — | — | US | claimed |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | BOS MICHAEL (CA) | 2002-07-11 | — | — | US | claimed |
| WO-2002047663-A1 | SELF EMULSIFYING LIPID MATRIX (SELM) | F. HOFFMAN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | claimed |
| US-6297375-B1 | 4-phenyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2001-10-02 | — | — | US | claimed |
| EP-1035115-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-13 | — | — | EP | claimed |